CEREBROSPINAL FLUID OXYTOCIN IN SCHIZOPHRENIC AND CONTROL SUBJECT

临床前研究表明，神经药理学与 催产素(OT)与行为、认知和神经化学改变 与精神分裂症有关。为了在临床上验证这些观察结果，我们 40例精神分裂症患者脑脊液OT浓度测定 15名对照组，采用竞争性放射免疫分析方法。脑脊液催产素 接受抗精神病药物治疗的患者的浓度没有统计学意义 与停药组不同。没有重大意义 精神分裂症组的平均值与精神分裂症组的平均值之间存在差异 健康组。

Preclinical studies have suggested a link between the neuropharmacology of oxytocin (OT) and changes in behavior, cognition, and neurochemistry associated with schizophrenia. To test these observations clinically, we measured the cerebrospinal fluid OT concentrations of 40 schizophrenic and 15 control subjects using a competitive radioimmunoassay. The CSF OT concentrations of neuroleptic-treated patients were not statistically different from those of the neuroleptic-withdrawn group. No significant differences were found between mean values of the schizophrenic group and the healthy group.